Seeking Alpha
30 Nov 2025, 03:08 UTC · 42w ago
Verdict
Headline leans bullish. We score SNDX +0.70 across four claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.70strongly bullish
What the story claims
4 claims · scored −1 bearish … +1 bullish
Syndax Pharmaceuticals projects 2026 revenue between $245M and $512M.
So whatConcrete future revenue guidance provides a baseline for valuation and growth expectations.
More positive than 91% of claims this week
Revuforj prescriptions increased by 25%, indicating an accelerating commercial ramp.
Continue reading
5 related stories
More positive than 79% of ticker scores this week
Scored by the NIS engine · methodology.
More positive than 84% of claims this week
Management is confident that existing cash reserves are sufficient to fund operations until the company reaches profitability.
So whatReduces the immediate risk of dilutive equity raises or liquidity crises.
More positive than 76% of claims this week
Syndax reported a slight revenue miss for the third quarter.
More negative than 68% of claims this week
Which stocks this story touches
More positive than 79% of ticker scores this week
Strong Q3 results, accelerating commercial ramp for key products, and confidence in reaching profitability.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
2d ago
−11.1%
Price is moving against the score
$17.62 vs $19.82 close before publication (Nov 28) · not market-adjusted
SNDX chart →
